[go: up one dir, main page]

MX2012008652A - Terapias para tratar infeccion por virus de hepatitis c. - Google Patents

Terapias para tratar infeccion por virus de hepatitis c.

Info

Publication number
MX2012008652A
MX2012008652A MX2012008652A MX2012008652A MX2012008652A MX 2012008652 A MX2012008652 A MX 2012008652A MX 2012008652 A MX2012008652 A MX 2012008652A MX 2012008652 A MX2012008652 A MX 2012008652A MX 2012008652 A MX2012008652 A MX 2012008652A
Authority
MX
Mexico
Prior art keywords
therapies
virus infection
treating hepatitis
patient
amount
Prior art date
Application number
MX2012008652A
Other languages
English (en)
Inventor
Nathalie Chauret
Maria Rosario
Shelley George
Tara Lynn Kieffer
Margaret James Koziel
Olivier Nicolas
Louise Proulx
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2012008652A publication Critical patent/MX2012008652A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para mejorar los farmacocinéticos de VX222 en un paciente infectado con HCV comprende la co-administración de VX-222 y VX-950 al paciente. Un método para tratar a un paciente infectado con HCV comprende administrar VX-222 y VX-950 al paciente, en donde VX-222 está en una cantidad de aproximadamente 20 mg a aproximadamente 400 mg, y en donde VX-950 está en una cantidad de aproximadamente 100 mg a aproximadamente 1,500 mg. Un método para tratar a un paciente infectado con HCV comprende administrar una cantidad terapéuticamente efectiva de VX-222, en donde VX-222 se administra en una cantidad de aproximadamente 20 mg a aproximadamente 2,000 mg una vez al día.
MX2012008652A 2010-01-29 2011-01-28 Terapias para tratar infeccion por virus de hepatitis c. MX2012008652A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29964310P 2010-01-29 2010-01-29
US30850610P 2010-02-26 2010-02-26
US30911710P 2010-03-01 2010-03-01
US32439510P 2010-04-15 2010-04-15
PCT/US2011/022854 WO2011094489A1 (en) 2010-01-29 2011-01-28 Therapies for treating hepatitis c virus infection

Publications (1)

Publication Number Publication Date
MX2012008652A true MX2012008652A (es) 2012-08-23

Family

ID=43901208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008652A MX2012008652A (es) 2010-01-29 2011-01-28 Terapias para tratar infeccion por virus de hepatitis c.

Country Status (14)

Country Link
US (1) US20130034522A1 (es)
EP (1) EP2528605A1 (es)
JP (1) JP2013518124A (es)
KR (1) KR20120139699A (es)
CN (1) CN102844030A (es)
AU (1) AU2011210795A1 (es)
CA (1) CA2788348A1 (es)
IL (1) IL220937A0 (es)
MX (1) MX2012008652A (es)
RU (1) RU2012136824A (es)
SG (1) SG182589A1 (es)
TW (1) TW201130502A (es)
WO (1) WO2011094489A1 (es)
ZA (1) ZA201205547B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2012006060A1 (en) * 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CH707030B1 (de) * 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
WO2013142159A1 (en) * 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100187613B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테이제 억제 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
EP1299527A2 (en) 2000-06-28 2003-04-09 National Research Council Of Canada Helicobacter dd-heptosyltransferase
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
KR20050040912A (ko) 2002-08-01 2005-05-03 파마셋 인코포레이티드 플라비비리다에 감염 치료용의 비사이클로[4.2.1]노난시스템을 가지는 화합물
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
BRPI0407587A (pt) 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
JP4550824B2 (ja) 2003-03-05 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎抑制化合物
US6908901B2 (en) 2003-03-05 2005-06-21 Boehringer Ingelheim International, Gmbh Hepatitis C inhibitor peptide analogs
WO2004103996A1 (en) 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
NZ545871A (en) 2003-09-12 2010-04-30 Vertex Pharma Animal model for protease activity and liver damage
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
PL1718608T3 (pl) 2004-02-20 2013-11-29 Boehringer Ingelheim Int Inhibitory polimerazy wirusowej
US20050288333A1 (en) 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
TWI437990B (zh) 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
CA2643688A1 (en) 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
AU2007227544B2 (en) 2006-03-16 2012-11-01 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
AU2007226983A1 (en) 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
AU2007226984B2 (en) 2006-03-20 2013-02-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
SG176488A1 (en) 2006-11-15 2011-12-29 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of flavivirus infections
MX2009006806A (es) 2006-12-22 2009-08-27 Vertex Pharma Secado por rocio fluidizado.
DK2114924T3 (da) 2007-02-27 2012-04-10 Vertex Pharma Co-krystaller og farmaceutiske sammensætninger omfattende disse
CN101854936A (zh) 2007-05-21 2010-10-06 弗特克斯药品有限公司 包含vx-950的剂型及其给药方案
MX2009013832A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
WO2010002998A1 (en) * 2008-07-03 2010-01-07 Gilead Sciences, Inc. 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS

Also Published As

Publication number Publication date
KR20120139699A (ko) 2012-12-27
CA2788348A1 (en) 2011-08-04
US20130034522A1 (en) 2013-02-07
JP2013518124A (ja) 2013-05-20
TW201130502A (en) 2011-09-16
EP2528605A1 (en) 2012-12-05
AU2011210795A1 (en) 2012-08-02
RU2012136824A (ru) 2014-03-10
IL220937A0 (en) 2012-09-24
WO2011094489A1 (en) 2011-08-04
CN102844030A (zh) 2012-12-26
ZA201205547B (en) 2013-04-24
SG182589A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
NZ732507A (en) Improved compositions for treating muscular dystrophy
NZ631155A (en) Combination of two antivirals for treating hepatitis c
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
PH12014500386A1 (en) Combination treatment for hepatitis c
HRP20180237T4 (hr) Metode za liječenje hcv-a
GEP20146134B (en) Inhibitors of hepatitis c virus replication
WO2008024843A3 (en) Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein
RU2015114543A (ru) Способы лечения гепатита с
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
IN2012MN02896A (es)
JP2012517478A5 (es)
RU2015114566A (ru) Способы лечения гепатита с
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
AR083337A1 (es) Tratamientos de infeccion por el virus de hepatitis c
RU2013129824A (ru) Новое лечение инфекции вируса гепатита с
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
RU2014116988A (ru) Алиспоривир для лечения инфекции, вызванной вирусом гепатита с
RU2012109938A (ru) Способ лечения вирусного гепатита с
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin

Legal Events

Date Code Title Description
FG Grant or registration